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Franco Grego, MD,a and Paolo Frigatti, MD,c Padua and Udine, Italy
Objective: Recent studies have shown that progressive renal dysfunction may develop in patients after endovascular
aneurysm repair (EVAR). Data are conﬂicting about the effect of EVAR on renal function compared with open repair
(OR). The purpose of this study was to compare the effects of EVAR, both with transrenal ﬁxation (TRF) and infrarenal
ﬁxation (IRF), vs OR on renal function detected with renal perfusion scintigraphy (RPS).
Methods: A prospective study was carried out from January 2003 to December 2007. Exclusion criteria included factors
that could inﬂuence post-procedural renal function as: preoperative creatinine clearance level <65 mL/min for men and
60 mL/min for women, renal artery stenosis >60%, renal accessory artery planned to be covered by the endograft, single
functioning kidney, hemodialysis, and kidney transplant. To evaluate renal function, an RPS was performed preopera-
tively, at 30 days, at 6 and 12 months, and then yearly. The glomerular ﬁltration rate (GFR) was estimated with the Gates
method.
Results: During the study period, 403 patients were enrolled; 243 (60%) had OR and 160 (40%) EVAR; among these, 83
(51%) had a TRF and 77 (48%) an IRF; 55 patients were excluded from the study. No statistical differences were observed
between groups for demographics and risk factors. Statistically signiﬁcant differences emerged between OR and EVAR
for early postoperative death (4% vs 0%; P[ .01). Follow-up ranged from 54 to 126 months (mean, 76 months) for OR
and from 54 to 124 months (mean, 74 months) for EVAR (P[ NS). Kaplan-Meier analysis survival rate at 9 years was
70% for OR and 58% for EVAR with a risk of secondary procedure of 9% and 34%, respectively (P < .0001). A deteri-
oration of the GFR was observed during the follow-up in both groups with a decrease after 9 years of 11% in the EVAR
group and 3% in the OR group respective to baseline (P < .001). A remarkable difference emerged on renal function
between EVAR patients who required a secondary procedure compared with the other EVAR patients (P < .005). No
signiﬁcant differences emerged between TFR and IRF for GFR decline during the follow-up period.
Conclusions: After EVAR, there is a continuous decline in renal function with respect to OR, regardless of ﬁxation level
and independently of pre-existing renal insufﬁciency. The risk of GFR impairment after EVAR should be taken into
consideration in selecting patients with preoperative renal insufﬁciency. (J Vasc Surg 2013;58:886-93.)Endovascular aneurysm repair (EVAR) has been shown
to be a suitable alternative to open repair (OR) for infrare-
nal abdominal aortic aneurysm (AAA), with good early and
mid-term results in appropriate candidates.1 The advan-
tages of EVAR have been reported and include decreased
morbidity, mortality, and length of stay, as well as a lower
overall treatment cost, especially with the last generation of
endoprosthesis.2,3
However, EVAR is associated with speciﬁc procedure
complications such as endoleak, stent graft migration,
and endograft limb occlusion, which require a secondary
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://dx.doi.org/10.1016/j.jvs.2013.02.249a close surveillance protocol, mainly based on serial
contrast-enhanced computed tomography (CT), is recom-
mended.1-3 Consequently, EVAR has the intrinsic poten-
tial effect to cause adverse events on renal function due
to endoluminal manipulations and contrast administration
during endograft deployment and secondary endovascular
procedures as well as for contrast nephropathy from repet-
itive serial CT scans.
Previous reports demonstrate a decrease of renal func-
tion after EVAR regardless of ﬁxation level, especially in
the long-term period, which appears to be more relevant
in patients with a pre-existing renal insufﬁciency.4-6 Recent
data are conﬂicting about the effect of EVAR on renal
function compared with OR.7,8
In all these papers, renal function has been evaluated by
serum creatinine or creatinine clearance estimated with the
Cockroft and Gault formula, which are inadequate to
demonstrate small changes and to detect worsening of
function of a single kidney.9,10
The renal perfusion scintigraphy (RPS) is one of the
most sensitive tests to detect renal dysfunction and especi-
ally to demonstrate the worsening of function limited to a
single kidney. Our previous report studying renal function
with RPS after EVARwith transrenal ﬁxation (TRF) showed
that there is kidney dysfunction after EVAR in 10.6% of
cases not associated with a serum creatinine variation.10
Fig 1. Study’s ﬂowchart. See text for more details. AAA, Abdominal aortic aneurysm; CT, computed tomography;
EVAR, endovascular aortic repair; IRF, intrarenal ﬁxation; OR, open repair; TRF, transrenal ﬁxation.
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the long-term outcomes of EVAR with OR with respect to
renal dysfunction as detected by RPS in patients without
a pre-existing renal insufﬁciency.
METHODS
Study design. A prospective cohort study was carried
out from January 2003 to December 2007 to compare the
long-term outcomes on renal function with EVAR vs OR.
The hypotheses of the study were that patients under-
going OR would demonstrate less decline in renal function
over time compared with those undergoing EVAR. In addi-
tion, we hypothesized that there would be no difference
over time in renal function for patients with EVAR with
infrarenal ﬁxation (IRF) compared with those with TRF.
Exclusion criteria included factors thought to potentially
inﬂuence postprocedure renal function and are listed in Fig 1.
Preoperative contrast-enhanced CT scans, with 3-mm
to 5-mm cuts, were obtained in all OR and EVAR
patients. On the basis of the contrast-CT scan, patients
were selected as possible candidates for EVAR. Three-
dimensional vascular reconstructions were performed using
the Osirix software (www.osirix-viewer.com). Contrast-
enhanced angiography and magnetic resonance angiog-
raphy were performed in selected cases.
OR was offered to patients with unsuitable anatomy,
including proximal infrarenal aortic neck less than 15 mmlong or greater than 30 mm in diameter, proximal neck
angulation greater than 60 degrees, extensive neck throm-
bus, access vessel calciﬁcations (more than 50% circum-
ference involvement) with tortuosity (angulation >60%),
common iliac or hypogastric arteries aneurysms greater
than 30 mm in diameter, and associated iliac occlusive
disease (complete obstruction or preocclusive stenosis
3 cm long). All the surgical procedures were performed
with the patient under general anesthesia and approached
routinely through a transperitoneal route with infrarenal
aortic clamping.
Anatomic criteria for exclusion from EVAR were less
stringent in patients at high risk. OR was also offered as
a ﬁrst option in patients with long life expectancy (>10
years), based on age and absence of signiﬁcant comorbid
conditions.
The endovascular procedure was always performed in
the operating room under general or epidural anesthesia.
An intraoperative digital angiography was performed after
the device deployment to identify any endoleaks and assess
the patency of renal arteries. The volume of contrast dye
used (Omnipaque; GE Healthcare, Ireland) was recorded.
Clinical and technical success was deﬁned according to the
reporting standards for endovascular repair.11
Renal function. Biochemical tests that are capable of
analyzing the functional status of the kidneys are not the
ideal tool to investigate renal function since large changes
Table I. Causes of exclusion from the study
Whole population
(N ¼ 458), No. (%)
Patients excluded from the study 55 (12)
Creatinine clearance <60 m/min 26
Renal artery stenosis >60% 11
Renal accessory artery planned to
be covered during EVAR
9
Single functioning kidney 4
Hemodialysis 3
Kidney transplant 2
EVAR, Endovascular aneurysm repair.
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and, even if creatinine clearance permits a more accurate
method to evaluate the glomerular ﬁltration rate (GFR),
this may be overestimated because of a variable tubular
secretion of creatinine.12-14 Furthermore, these tests do
not give information about the function of each kidney.
Thus, a direct measurement of GFR is necessary to precisely
evaluate renal function. RPS is a sensitive test to detect GFR;
it is able to evaluate separately the function of the kidneys
and to identify subtle renal functional loss.9 Therefore, we
decided to use the RPS performed using a technetium-99-m
diethylene triamine penta-acetic acid to evaluate renal
function. The GFR was estimated with the Gates method.15
The RPS was performed preoperatively, and postoper-
atively at 30 days, at 6 and 12 months, and annually there-
after. A decrease of $20% of the GFR was considered
relevant.10
To prevent contrast nephropathy, patients were treated
with N-acetylcysteine (NAC), 600 mg orally twice a day
for 1 day before and 2 days after EVAR, and for any other
contrast study during the follow-up period. Furthermore,
all patients who underwent angiography or angio-CT
received hydration as guidelines recommend, and all neph-
rotoxic drugs (diuretics, angiotensin-converting-enzyme
inhibitors, angiotensin receptor blockers, nonsteroidal
anti-inﬂammatory drugs) were withdrawn 24 hours before
contrast exposure.14
Patients who underwent EVAR had an angio-CT per-
formed postoperatively at 30 days, at 6 and 12 months, and
annually thereafter. In the OR group, follow-up consisted
of annual duplex ultrasound scanning.
In patients with postprocedural renal dysfunction,
GFR <65 mL/min in men and <60 mL/min in women,
the post-EVAR surveillance was based on abdominal CT
scan without contrast dye and ultrasound Doppler.
Statistical analysis. Before starting the study, we
calculated the sample size for each of the cohorts necessary
to evaluate these hypotheses. A retrospective review of our
data concerning results in patients who underwent EVAR
who ﬁt with the inclusion criteria reported revealed a post-
operative renal function impairment of 10.5%. On the basis
of these data, 948 patients (474 in each group) would have
been required to produce a statistically signiﬁcant differ-
ence between EVAR and OR.
The main assumptions for this calculation were that
postoperative renal function impairment with OR was
expected to be 5%, and the study power was 80% at
P ¼ .05. We calculated that to enroll 984 patients would
require more than 15 years. We decided to perform the
study using a more accurate test to detect renal function
with a lesser number of patients to address the consequent
power limitation.
Review of our previous experience with RPS after
EVAR,10 in a population of patients ﬁtting with the inclu-
sion criteria of the current study, showed a postprocedural
GFR impairment of about 15%. On the basis of these data,
688 patients (344 in each group) would have been
required to produce a statistically signiﬁcant differencebetween EVAR and OR (study power 80%; P ¼ .05).
Nevertheless, we decided to perform the study accepting
the power limitation, since it was the ﬁrst prospective study
speciﬁcally designed to detect the long-term outcome on
renal function after OR and EVAR using RPS. A 5-year
period of enrollment was chosen to ensure, at minimum,
150 patients in each group.
Comparisons between the two groups were performed
with the Student t-test or the Mann-Whitney U test for
continuous variables and the c2 analysis or Fisher exact
test for discrete variables. Rates of freedom from any death
and need for secondary procedures were estimated with the
Kaplan-Meier method, with the log-rank test for signiﬁ-
cance. A P value of <.05 was considered statistically signif-
icant. All statistical analyses were conducted with SPSS
software (SPSS Inc, Chicago, Ill).
RESULTS
During the study period from January 2003 to
December 2007, 458 consecutive patients were operated
on for infrarenal AAA. Among these, 177 (39%) patients
underwent EVAR; 81 had an IRF (Excluder; W.L. Gore
& Associates, Flagstaff, Ariz) and 96 had a TRF (Zenith;
Cook Inc, Indianapolis, Ind).
Fifty-ﬁve patients (12.1%) were excluded from the
study (Fig 1, Table I). Of the 243 patients undergoing
OR, 126 (52%) received a bifurcated aorto-iliac grafts, 98
(40%) received tubular aorto-aortic grafts, and the remain-
ing 19 (8%) received bifurcated aortofemoral grafts.
The mean infrarenal aortic cross clamping time was
15.4 6 5.6 min.
The mean AAA diameter was 5.9 6 0.4 cm (range,
5.3-6.5 cm) in patients with OR and 6.1 6 0.5 cm (range,
5.5-6.8 cm) in EVAR. No statistical differences were
observed between groups for demographics and risk
factors, classiﬁed according to the Society for Vascular
Surgery/International Society for Cardiovascular Surgery
reporting standards,16 except for the American Society of
Anesthesiologists (ASA) score, chronic pulmonary occlu-
sive, and coronary artery disease, which were signiﬁcantly
higher in the EVAR group (Table II).
In the OR group, nine (4%) patients died in the early
postoperative period; four of myocardial infarction, three
after a sigmoid infarction, and two for a major arrhythmia.
Table II. Demographic data and risk factors
OR
(n ¼ 243)
EVAR
(n ¼ 160) P
Mean age (range) 71.7 (58-85) 72.3 (57-87) NS
Male/female 198/45 150/10 NS
Hypertension 198 (81) 126 (79) NS
Coronary artery disease 84 (34) 85 (53) .003
Diabetes mellitus 69 (28) 56 (35) NS
Pulmonary disease 49 (20) 76 (47) <.0001
Tobaco use 154 (63) 117 (73) NS
Cerebrovascular disease 28 (11) 22 (14) NS
Hyperlipidemia 75 (31) 49 (31) NS
ASA classiﬁcation IV 11 (4) 41 (26) <.0001
ASA, American Society of Anesthesiologists; EVAR, endovascular aneurysm
repair; OR, open repair.
Continuous data are shown as mean (range) and categoric data as number (%).
Table III. Causes of death during the follow-up period
(mean, 76 months; range, 54-126 months)
EVAR
(n ¼ 31), No. (%)
OR
(n ¼ 28), No. (%)
Cardiac 9 (29) 8 (29)
Pulmonary 8 (26) 7 (25)
Malignancy 6 (19) 5 (18)
Sudden death 3 (10) 3 (11)
Stroke 3 (10) 4 (14)
Suicide 2 (6) 1 (4)
EVAR, Endovascular aneurysm repair; OR, open repair.
Fig 2. Survival in patients undergoing open repair (OR) and
endovascular aneurysm repair (EVAR) (Kaplan-Meier analysis).
Standard errors of displayed data did not exceed 10%.
Table IV. Secondary procedures after EVAR and OR
EVAR
(n ¼ 160),
No. (%)
OR
(n ¼ 243),
No. (%)
Patients with secondary procedures 28 (17) 8 (3)
Inferior mesenteric or lumbar artery
embolization for type II endoleak
14
Aortic or iliac endograft extension
for type I endoleak
4 –
Femorofemoral crossover 2 2
Fibrinolysis and balloon angioplasty 2 –
Laparoscopic inferior mesenteric
artery clipping
2 –
Renal artery stenting 2 –
Graft limb thrombectomy 1 1
Conversion to OR 1 –
Incisional hernia repair – 3
Infected graft replacement – 2
EVAR, Endovascular aneurysm repair; OR, open repair.
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cases (1%) required a femoro-femoral crossover in the early
postoperative period for branch occlusion. The angio-CT
scan performed after 30 days from the procedure showed
the presence of a type II endoleak in 25 cases (15%).
No device migration was observed, and there were no
perioperative deaths in the EVAR group.
A signiﬁcant statistical difference emerged between OR
and EVAR for early postoperative death (4% vs 0%; P¼ .01).
Follow-up ranged from 54 to 126 months (mean,
76 months) for OR and from 54 to 124 months (mean,
74 months) for EVAR (P ¼ NS). Causes of death during
follow-up are listed in Table III. At Kaplan-Meier analysis
survival rate at 9 years was 70% for OR and 58% for
EVAR. No signiﬁcant statistical difference emerged at the
log-rank test (Fig 2).
At least one secondary procedure was performed in
17% of patients who underwent EVAR, compared with
3% of patients in the OR group (P < .0001). Secondary
procedures in the EVAR and OR groups are listed in
Table IV. Kaplan-Meier analysis at 9 years showed a 34%
risk for secondary procedure in the EVAR group and 9%
in the OR group (P < .0001; Fig 3).
Results on renal function. The mean volume of
contrast dye used in EVAR patients was 148 6 10 mL
(range, 125-170 mL).
No signiﬁcant changes were observed for mean creati-
nine clearance by RPS from the preoperative to thepostoperative period (30th day) in either EVAR or OR
groups (Table V). Otherwise, analyzing the results of the
RPS in each patient, a signiﬁcant change was observed in
22 (14%) of the EVAR group and in 11 (4%) of the OR
group (P < .001; Table V). Noteworthy in nine patients
of the EVAR group, the GFR impairment was limited to
a single kidney. In these cases, the renal function impair-
ment remained stable during the follow-up.
In the OR group, no relationship emerged between
the type of aortic reconstruction, the time of aortic cross
clamping, and the early decline of renal function.
A deterioration of the GFR was observed during the
follow-up in both groups and was more marked in the
EVAR group (P < .001). In these patients, the GFR
continuously declined through all the follow-up period,
with a decrease after 9 years of 11% with respect to the
baseline (Fig 4). In the OR group, there was a decline in
the GFR at 6 months after surgery (6% with respect to
baseline), with a complete normalization of the GFR
from baseline at 48 months (decrease of 2%) and a reduc-
tion at 9 years of 3%.
Considering the results on renal function in patients of
the EVAR group that required a secondary procedure,
Fig 3. Freedom from secondary procedure in patients undergoing
open repair (OR) and endovascular aneurysm repair (EVAR)
(Kaplan-Meier analysis). Standard errors of displayed data did not
exceed 10%.
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period with respect to the other EVAR patients. In fact,
in this subgroup of patients, the decline of the GFR was
remarkably higher, with a reduction at 9 years of 14%
with respect to 7% (P < .005; Fig 5). In this subgroup of
patients, the mean volume of contrast dye used to perform
the secondary procedure and the subsequent control
angio-CT at 30 days was 223 6 36 mL. Furthermore, by
comparing the GFR between OR and EVAR patients
who did not require a secondary procedure, a signiﬁcant
difference was still present (P < .0005).
The angio-CT scan and the ultrasound Doppler
demonstrated the patency of the renal arteries in both
groups in the absence of signiﬁcant stenosis.
No signiﬁcant variations of mean GFR was observed
from the preoperative to the postoperative period (30th
day) in either the TRF or IRF group (Table V). Also in
both groups, about 40% of patients present a signiﬁcant
RPS impairment focused to a single kidney (Table V).
No differences emerged between the two groups for
GFR variation during the follow-up period (Fig 6).
DISCUSSION
This is the ﬁrst prospective study that evaluates renal
function with RPS in patients who underwent EVAR and
OR for infrarenal AAA in the absence of preoperative renal
failure and renal artery stenosis. These patient selection
criteria were adopted in order to eliminate pre-existing renal
diseases that may inﬂuence postoperative renal dysfunction.
This study demonstrated a marked decline over the
time in renal function in EVAR compared with OR
patients (P < .001) that started in the early postoperative
period (13% vs 4%; P < .001) and persisted through all
the follow-up, with a reduction of the GFR at 9 years of
11% compared with 3%.
Some factors argued to be responsible for such obser-
vations include pre-existing renal insufﬁciency, age over
70 years, the type of device used (TRF vs IRF), the repet-
itive administration of contrast agent during the follow-
up period, and the need for secondary endovascular
procedures.7,8However, data on literature regarding this topic are still
conﬂicting. A recent meta-analysis reported no difference
in renal function after EVAR compared with OR, but the
authors were not able to draw a strong conclusion since
most studies considered were short-term, and the deﬁni-
tion of renal function impairment was highly variable.17
Furthermore, in all these studies, renal function was assayed
by biochemical tests, which are capable means of analyzing
the functional status of the kidneys but are relatively insen-
sitive. A large change in renal function must occur before
the biochemical test is signiﬁcantly altered.12,13 Addition-
ally, these biochemical tests do not give information about
the function of each kidney. Thus, a direct measurement of
GFR is necessary to precisely evaluate renal function.
RPS is one of the most sensible tests that detect GFR,
separately evaluate the function of the kidneys, and identify
subtle renal functional loss.9
RPS in the OR group showed an initial decline in renal
function (6% at 6 months) with complete normalization by
48 months (2% decrease). This transient dysfunction after
OR could be related to the hemodynamic effect of aortic
cross-clamping, reperfusion injury, blood loss, transient
hypotension, and perioperative ﬂuid shifts.
It is noteworthy that the RPS revealed a signiﬁcant
reduction (>20%) of the GFR in nine (6%) EVAR patients
(four with TRF and ﬁve with IRF) that was limited to
a single kidney. The causes responsible for this worsening
may be ascribed to micro-embolism during the endovascu-
lar procedure such as manipulation of the endograft within
the aortic neck near the renal ostia and balloon expansion
of the proximal stent. Findings of punctate renal infarctions
on follow-up CT scans have been noted in various studies,
suggesting a possible embolic sequela after EVAR.4,18
Contrast-induced renal insufﬁciency has been well
documented and could explain the impairment of renal
function observed in the EVAR group. Moreover, the
repeat use of iodine dye during the follow-up period may
also be responsible for the continuous renal function
decline noted in the long-term period. In our experience,
patients were always treated with N-acetylcysteine
600 mg orally twice a day for 1 day before and 2 days after
EVAR and for any other contrast study during the follow-
up period. Moreover, all patients who underwent angiog-
raphy or angio-CT at our institution received hydration
as guidelines recommend, and all nephrotoxic drugs
(diuretics, angiotensin-converting-enzyme inhibitors, an-
giotensin receptor blockers, nonsteroidal anti-inﬂammatory
drugs) were withdrawn 24 hours before contrast expo-
sure.14 The issue of contrast nephropathy could be particu-
larly relevant in patients who required one or more
adjunctive endovascular procedures with the follow-up
mainly based on angio-CT. The results of our study demon-
strated a close relation between adjunctive procedures
performed in the long-term and the decline in renal func-
tion. In fact, in the 24 patients (17%) that required a sup-
plementary endovascular procedure during the follow-up,
the decline of the GFR at 9 years was remarkably higher
(P < .0005).
Table V. Early results on renal function at the RPS
OR (n ¼ 243) EVAR (n ¼ 160) TRF (n ¼ 87) IRF (n ¼ 83)
Preoperative
Postoperative
(30th day) Preoperative
Postoperative
(30th day) Preoperative
Postoperative
(30th day) Preoperative
Postoperative
(30th day)
GFR at RPS,a
mL/min
94.8 6 8.1 89.5 6 8.2 91.5 6 9.1 86.5 6 8.2 92.2 6 11.3 87.4 6 12.2 90.3 6 16.2 85.4 6 14.3
Patients with
postoperative
GFR
11 (4)b 22 (14) 10 (11) 12 (14)
Patients with
postoperative
GFR impairment
of a single kidney
0 9 (40)c 4 (40) 5 (42)
EVAR, Endovascular aneurysm repair; GFR, glomeular ﬁltration rate; IRF, intrarenal ﬁxation; OR, open repair; RPS, renal perfusion scintigraphy; TRF,
transrenal ﬁxation.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
aGFR at the RPS estimated with the Gates method.
bP < .001 and between OR and EVAR.
cP ¼ .0001.
Fig 4. Comparison of the long-term results on renal function at
the renal perfusion scintigraphy (RPS), between patients under-
going open repair (OR) and endovascular aortic repair (EVAR)
(P < .0001). GFR, Glomerular ﬁltration rate.
Fig 5. Comparison of the long-term results on renal function at the
renal perfusion scintigraphy (RPS), between patients undergoing
endovascular aortic repair (EVAR) and EVAR with secondary
procedure (P < .005). GFR, Glomerular ﬁltration rate.
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contrast dye used in these cases. To avoid such types of
complications, a follow-up protocol consisting of an intra-
operative completion angiogram, ultrasound Doppler scans
(with or without contrast), and plain abdominal radiog-
raphy, which have been shown to have a high sensitivity
and negative predictive value, could be used to reduce
the contrast dye exposure.19,20 In our series as well in other
reports, correction of a type II endoleak was the main cause
for a secondary procedure. Furthermore, these procedures
do not always guarantee a solution to the problem. The
literature reports a secondary interventional success rate
of 43%, and in some cases, the only deﬁnitive solution
could be surgical conversion.21
Recently, there has been a new trend toward preventing
type II endoleak with aneurysmal sac and lumbar artery
embolization using coils and ﬁbrin glue at the time of
EVAR.22,23 This may reduce the increased risk for sec-
ondary procedures in EVAR compared with OR patients
(P < .001 in the present study), and the subsequent decline
of the GFR related to the contrast dye exposure.The inﬂuence of suprarenal vs IRF on renal function
has been studied and is still in debate.24,25 Flow impair-
ment due to bare stents across the ostia of the renal artery
may be a contributing factor in renal function decline.
Moreover, experimental data in pigs seems to shows that
bare stents may compromise long-term renal perfusion as
a result of neointimal ingrowth between the stent struts.26
A meta-analysis of these studies provided conﬂicting
results and concluded that the data were insufﬁcient to
draw any strong conclusions on the effect of TRF and
IRF on renal function.27
In this study, no signiﬁcant variations of the GFR were
observed between TRF and IRF. Furthermore, in both
groups, about 40% of patients demonstrated a signiﬁcant
RPS impairment conﬁned to a single kidney, suggesting
that the risk of renal micro-embolization during EVAR is
not related to the ﬁxation level.
To limit renal function impairment after EVAR, we
have radically modiﬁed our approach since currently we
Fig 6. Comparison of the long-term results on renal function at the
renal perfusion scintigraphy (RPS), between patients undergoing
endovascular aortic repair (EVAR) with transrenal ﬁxation (TRF)
and intrarenal ﬁxation (IRF). GFR, Glomerular ﬁltration rate.
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the subsequent number of secondary procedures by per-
forming an intraoperative aneurysmal sac embolization.28
Furthermore, we have revised our surveillance protocol
that currently is based on abdominal CT without contrast
dye and ultrasound Doppler. Angio-CT is performed only
in case of aneurysmal sac enlargement, persistent type II
endoleak, or signs of endograft migration.
Some limitations exist since the study is underpowered
with a smaller number of patient enrolled in the EVAR
group with respect to OR (ratio of 1.5) and a greater
number of ASA score IV patients (P < .0001) that may
inﬂuence results on renal function, especially in the long-
term. Furthermore, the number of patients enrolled limits
the ability to perform meaningful subgroup analysis and
to identify statistically signiﬁcant risk factors for progressive
renal function decline (type II error).
CONCLUSIONS
After EVAR, there is a continuous decline in renal
function compared with OR, regardless of ﬁxation level
and independently of a pre-existing renal insufﬁciency.
The renal function impairment is probably related to the
administration of contrast agent and/or to micro-
embolism during procedural maneuvers. The RPS is, in
our opinion, a useful test to correctly evaluate renal func-
tion after EVAR and to localize the impaired kidney. The
risk of GFR impairment after EVAR both with TRF or
IRF should be taken into consideration in selecting patients
with preoperative renal insufﬁciency.
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J Vasc Surg 2013;57:934-41.Submitted Sep 2, 2012; accepted Feb 16, 2013.INVITED COMMENTARYMaciej L. Dryjski, MD, PhD, Buffalo, NYOver the years, several studies have been published comparing
renal function after endovascular aneurysm repair (EVAR) and
open repair, as well as EVAR with transrenal and infrarenal graft
ﬁxation. Results of these investigations have been inconsistent,
which could be attributed to both the methodology itself as well
as to an often multifactorial etiology of chronic renal failure in
these patients. Dr Antonello and colleagues’ work distinguishes
itself with a very long follow-up period and a more sensitive
method to assess renal function. The study is prospective and
non-randomized, with less than 40% of patients being recruited
to the EVAR cohort. The traditional approach was preferred in
patients with long-life expectancy and individuals with unsuitable
anatomy for EVAR, applying very conservative anatomical exclu-
sion criteria for good-risk patients and different, much less strin-
gent criteria for patients at high risk. In addition, there were
signiﬁcantly more American Society of Anaesthesiologists class
IV patients and patients with coronary and pulmonary disease
recruited into the EVAR group (4% vs 26%, 34% vs 53%, and
20% vs 47%, respectively). Thus, it seems that there was a bias in
patient selection which ultimately may have altered the outcome
of the analysis. Furthermore, the authors implied that at least20% decrease of glomular ﬁltration rate calculated with renal perfu-
sion scintigraphy (RPS) is needed to be considered relevant. In
EVAR patients, the decrease was 11% at 108 months, and in the
EVAR cohort requiring reinterventions, the mean RPS decrease
was no more than 14%. The only signiﬁcant decrease in RPS was
limited to one kidney and most likely resulted from microemboli-
zation during the procedure. It remains unclear what clinical
signiﬁcance a slight decrease in RPS may have on overall renal
function and ultimately a patient’s life expectancy.
Finally, the follow-up protocol required at least four computed
tomography angiographies in the ﬁrst year in addition to a peri-
operative angiogram. The cumulative volume of contrast media
given to these patients is probably the single most important factor
affecting renal function. This is also supported by the fact that
patients exposed for multiple reinterventions, which often require
administration of signiﬁcant volume of dye, were particularly prone
todevelop renal insufﬁciency.DrAntonello indicated that, as a result
of this study, he modernized his surveillance protocol, replacing
frequent computed tomography angiographies with ultrasound
exams, and I think this is the most important take-home lesson
from this article.
